What is the catalog number for Avanafil-13C, d3?

The catalog number for Avanafil-13C, d3 is HY-18252S.

What sizes are available for Avanafil-13C, d3?

Avanafil-13C, d3 is available in the following size(s): 1 mg.

Is Avanafil-13C, d3 in stock?

Avanafil-13C, d3 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Avanafil-13C, d3?

Avanafil-13C, d3 is manufactured by QuantiMol.

What is the estimated delivery time for Avanafil-13C, d3?

Estimated delivery time for Avanafil-13C, d3 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Avanafil-13C, d3?

The safety data sheet for Avanafil-13C, d3 is available here: http://file.medchemexpress.com/batch_PDF/HY-18252S/.

Avanafil-13C, d3

Avanafil-13C, d3 is the 13C- and deuterium labeled Avanafil.

Product Specifications

CAS Number

2738376-89-9

Product Name Alternative

TA1790-13C, d3

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Phosphodiesterase (PDE)

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Solubility

10 mM in DMSO

Smiles

ClC1=C(O[13C]([2H])([2H])[2H])C=CC(CNC2=C(C(NCC3=NC=CC=N3)=O)C=NC(N4[C@H](CO)CCC4)=N2)=C1

Molecular Formula

C22 13CH23D3ClN7O3

Molecular Weight

487.96

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-223.|[2]Kotera J, et al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012 Aug;188 (2) :668-74.|[3]Mochida H, et al. Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs. J Urol. 2013 Aug;190 (2) :799-806.|[4]Wang R, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med. 2012 Aug;9 (8) :2122-9.